To install click the Add extension button. That's it.

The source code for the WIKI 2 extension is being checked by specialists of the Mozilla Foundation, Google, and Apple. You could also do it yourself at any point in time.

How to transfigure the Wikipedia

Would you like Wikipedia to always look as professional and up-to-date? We have created a browser extension. It will enhance any encyclopedic page you visit with the magic of the WIKI 2 technology.

Try it — you can delete it anytime.

Install in 5 seconds
4,5
Kelly Slayton
Congratulations on this excellent venture… what a great idea!
Alexander Grigorievskiy
I use WIKI 2 every day and almost forgot how the original Wikipedia looks like.
Live Statistics
English Articles
Improved in 24 Hours
Added in 24 Hours
Languages
Recent
Show all languages
What we do. Every page goes through several hundred of perfecting techniques; in live mode. Quite the same Wikipedia. Just better.
Great Wikipedia has got greater.
.
Leo
Newton
Brights
Milds

Larotrectinib

From Wikipedia, the free encyclopedia

Larotrectinib
Clinical data
Trade namesVitrakvi
Other namesLOXO-101, ARRY-470
AHFS/Drugs.comMonograph
MedlinePlusa619006
License data
Pregnancy
category
  • AU: D
Routes of
administration		By mouth, oropharyngeal
ATC code
Legal status
Legal status
Identifiers
  • (3S)-N-{5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl}-3-hydroxypyrrolidine-1-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC21H22F2N6O2
Molar mass428.444 g·mol−1
3D model (JSmol)
  • O[C@H]1CCN(C1)C(=O)Nc2cnn3ccc(nc23)N4CCC[C@@H]4c5cc(F)ccc5F
  • InChI=1S/C21H22F2N6O2/c22-13-3-4-16(23)15(10-13)18-2-1-7-28(18)19-6-9-29-20(26-19)17(11-24-29)25-21(31)27-8-5-14(30)12-27/h3-4,6,9-11,14,18,30H,1-2,5,7-8,12H2,(H,25,31)/t14-,18+/m0/s1
  • Key:NYNZQNWKBKUAII-KBXCAEBGSA-N

Larotrectinib, sold under the brand name Vitrakvi, is a medication for the treatment of cancer.[4][5][6] It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC.[7][8][9] It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013.

Larotrectinib was initially awarded orphan drug status in 2015, for soft tissue sarcoma, and breakthrough therapy designation in 2016 for the treatment of metastatic solid tumors with NTRK fusion.[10] Some clinical trial results were announced in 2017.[11] On 26 November 2018, Larotrectinib was approved by the FDA.[12]

Larotrectinib was the first drug to be specifically developed and approved to treat any cancer containing certain mutations, as opposed to cancers of specific tissues (i.e., the approval is "tissue agnostic"). Several earlier drugs, including pembrolizumab, were eventually approved by the FDA for treatment of specific mutations independent of the type of cancer, but those drugs had been initially developed for specific cancer types.[13] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[14]

Phase II clinical trials evaluating the drug for efficacy and safety in treating several types of solid tumors are ongoing.[15]

Larotrectinib was approved for medical use in the European Union in September 2019.[16][17] It was approved for medical use in Australia in August 2020.[4]

YouTube Encyclopedic

  • 1/5
    Views:
    1 228
    973
    756
    908
    559
  • Larotrectinib for Solid Tumors With NTRK Gene Fusions
  • How Will Larotrectinib Be Used?
  • Dr. Drilon Discusses the FDA Approval of Larotrectinib
  • The impact of TRK inhibitor LOXO-101 (larotrectinib) on patients with TRK fusion cancers
  • Dr. Demetri on Larotrectinib in TRK-Fusion GI Cancers

Transcription

References

  1. ^ "Vitrakvi Product information". Health Canada. 25 April 2012. Retrieved 29 May 2022.
  2. ^ "Summary Basis of Decision (SBD) for Vitrakvi". Health Canada. 23 October 2014. Retrieved 29 May 2022.
  3. ^ "Vitrakvi 25mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 7 March 2022. Retrieved 28 November 2022.
  4. ^ a b "Vitrakvi". Therapeutic Goods Administration (TGA). 16 September 2020. Retrieved 22 September 2020.
  5. ^ "Vitrakvi- larotrectinib capsule Vitrakvi- larotrectinib solution, concentrate". DailyMed. 26 July 2019. Retrieved 22 September 2020.
  6. ^ "STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL" (PDF). ama-assn.org. 26 October 2016.
  7. ^ Berger S, Martens UM, Bochum S (2018). "Larotrectinib (LOXO-101)". Small Molecules in Oncology. Recent Results in Cancer Research. Vol. 211. pp. 141–151. doi:10.1007/978-3-319-91442-8_10. ISBN 978-3-319-91441-1. PMID 30069765. {{cite book}}: |journal= ignored (help)
  8. ^ Federman N, McDermott R (October 2019). "Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer". Expert Review of Clinical Pharmacology. 12 (10): 931–939. doi:10.1080/17512433.2019.1661775. PMID 31469968.
  9. ^ Scott LJ (February 2019). "Larotrectinib: First Global Approval". Drugs. 79 (2): 201–206. doi:10.1007/s40265-018-1044-x. PMID 30635837. S2CID 57772716.
  10. ^ "Larotrectinib". AdisInsight. Retrieved 31 January 2017.
  11. ^ Novel Agent Shows Antitumor Activity in TRK-Fusion Cancers. June 2017
  12. ^ "FDA approves larotrectinib for solid tumors with NTRK gene fusions". U.S. Food and Drug Administration (FDA). 26 November 2018.
  13. ^ Dun L (27 November 2018). "FDA approves a new cancer drug targeted to genetic mutation, not cancer type". NBC. Retrieved 3 December 2018.
  14. ^ New Drug Therapy Approvals 2018 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2019. Retrieved 16 September 2020.
  15. ^ Bayer (17 February 2023). "A Phase 2 Basket Study of the Oral TRK Inhibitor Larotrectinib in Subjects With NTRK Fusion-positive Tumors" – via ClinicalTrials.gov. {{cite journal}}: Cite journal requires |journal= (help)
  16. ^ Gallagher J (23 September 2019). "'Revolutionary' new class of cancer drugs approved". Retrieved 30 September 2019.
  17. ^ "Vitrakvi EPAR". European Medicines Agency (EMA). 23 July 2019. Retrieved 22 September 2020.

External links


Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

This page was last edited on 22 January 2024, at 01:11
Basis of this page is in Wikipedia. Text is available under the CC BY-SA 3.0 Unported License. Non-text media are available under their specified licenses. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. WIKI 2 is an independent company and has no affiliation with Wikimedia Foundation.
Contact WIKI 2
Introduction
Terms of Service
Privacy Policy